Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based Boehringer Ingelheim has entered into a research alliance with the University of Toronto through the Toronto Recombinant Antibody Centre (TRAC), together with Toronto-based University Health Network and Mount Sinai Hospital to investigate new therapeutic targets in the field of ubiquitin signalling biology.
Subscribe to our email newsletter
The ubiquitin system alterations are related to many common diseases, including cancer, diabetes, inflammation and several central nervous system (CNS) disorders.
Scientists from Boehringer and the Toronto academic community will work together to explore different therapeutic concepts within the ubiquitin system.
As part of the deal, research capabilities of the three research institutes and Boehringer will be brought together to offer new starting points for drug discovery in a multi-year research program focusing on the development and characterization of new ubiquitin binding variants developed at the TRAC.
Boehringer Ingelheim Research and Non-clinical Development senior corporate vice-president Michel Pairet said the company is happy to work closely in a joint research program with the distinguished scientists at the University of Toronto, the University Health Network and the Mount Sinai Hospital in this emerging field of breakthrough therapeutics.
"We believe that this research program, headed by Sachdev Sidhu at the University of Toronto, will further strengthen our strong commitment in initiating new drug discovery programmes in areas of high unmet medical need," Pairet said.
Image: Boehringer Ingelheim Center (BIC), corporate headquarters building in Ingelheim, Germany. Photo: courtesy of Boehringer Ingelheim GmbH.